TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07593144: A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instabi

Sponsor: Foresight Therapeutics (Hefei) Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 156 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,754,440

Rescue Site Savings

+$4,461,072

Unlock Full NCT07593144 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07593144 Rescue Dossier →